drugset / Trial / NCT00175955

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

NCT00175955

Phase 2 Completed 70 enrolled UCB Pharma
RandomizedParallel-groupDouble-blind

Summary

An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia

Timeline

Start
2005-05
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 3000 mg Oral

Indications